EXPRESSION OF GROWTH HORMONE-RELEASING HORMONE RECEPTORS IN APOCRINE ADNEXAL TUMOURS AND APOCRINE GLANDS OF THE SKIN

被引:4
作者
Kovari, Bence [1 ]
Kocsis, Lajos [2 ]
Varga, Erika [3 ]
Cserni, Gobor [1 ,2 ]
机构
[1] Univ Szeged, Inst Pathol, Allomas U 1, H-6720 Szeged, Hungary
[2] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Kecskemet, Hungary
[3] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary
关键词
skin adnexal tumours; sweat gland; apocrine gland; growth hormone-releasing hormone receptor; immunohistochemistry; BREAST CARCINOMAS; GHRH; CANCERS;
D O I
10.5114/pjp.2018.75336
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Encouraged by our previous finding of growth hormone-releasing hormone receptor (GHRH-R) expression in metaplastic and neoplastic apocrine breast epithelium, we examined a small series of skin adnexal tumours with various degrees of apocrine (oxyphilic) differentiation, as well as normal axillary and anogenital apocrine sweat glands, for the expression of GHRH-R. Sections of formalin-fixed paraffin-embedded tissue blocks were immunostained for gross cystic disease fluid protein-15 (GCDFP-15) and androgen receptor (AR), to prove apocrine differentiation and correlate it with areas of GHRH-R expression. All but one of 19 tumours with apocrine epithelium and all five benign apocrine glands stained with both anti-GHRH-R antibodies used, each labelling a different domain of the receptor. Non-apocrine areas of the tumours and four eccrine tumours without oxyphilic features did not stain, but most sebaceous glands and some eccrine glands were labelled. Our data suggest that anti-GHRH-R antibodies highlight apocrine differentiation at extramammary sites also. Although GHRH-R seems to have a sensitivity comparable to classic apocrine markers such as AR and GCDFP-15, it seems to be inferior in specificity. The GHRH-R labelling of apocrine glands and neoplastic epithelium might also interfere with the emerging anti-GHRH targeted treatment of some malignancies acting on these receptors.
引用
收藏
页码:48 / 52
页数:5
相关论文
共 8 条
[1]   Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines [J].
Barabutis, N. ;
Schally, A. V. .
BRITISH JOURNAL OF CANCER, 2008, 98 (11) :1790-1796
[2]   Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers [J].
Kahán, Z ;
Arencibia, JM ;
Csernus, VJ ;
Groot, K ;
Kineman, RD ;
Robinson, WR ;
Schally, AV .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (02) :582-589
[3]  
Kazakov DV., 2012, Cutaneous Adnexal Tumors, P1
[4]   The expression of GHRH and its receptors in breast carcinomas with apocrine differentiation-further evidence of the presence of a GHRH pathway in these tumors [J].
Kovari, Bence ;
Vranic, Semir ;
Marchio, Caterina ;
Sapino, Anna ;
Cserni, Gabor .
HUMAN PATHOLOGY, 2017, 64 :164-170
[5]   Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive [J].
Kovari, Bence ;
Rusz, Orsolya ;
Schally, Andrew V. ;
Kahan, Zsuzsanna ;
Cserni, Gabor .
APMIS, 2014, 122 (09) :824-831
[6]  
Perez Roberto, 2014, Oncoscience, V1, P665
[7]   Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers [J].
Seitz, S. ;
Rick, F. G. ;
Schally, A. V. ;
Treszl, A. ;
Hohla, F. ;
Szalontay, L. ;
Zarandi, M. ;
Ortmann, O. ;
Engel, J. B. ;
Buchholz, S. .
ONCOLOGY REPORTS, 2013, 30 (01) :413-418
[8]  
Vranic S, 2013, HISTOL HISTOPATHOL, V28, P1393, DOI 10.14670/HH-28.1393